Meridian launches a novel SARS-CoV-2 antibody pair designed for developing highly sensitive rapid antigen tests from saliva s...
September 14 2020 - 9:00AM
Meridian Bioscience, Inc. (NASDAQ: VIVO), a leading provider of
diagnostic testing solutions and life science critical raw
materials, is pleased to announce the launch of a novel highly
sensitive SARS-CoV-2 antibody pair to the trimeric spike protein to
accelerate development of COVID-19 assays from patient saliva.
Coronavirus-neutralizing antibodies primarily target the trimeric
spike (S) glycoprotein on the viral surface that mediates entry
into the host cell. This antibody pair binds to recombinant
SARS-CoV-2 trimeric spike protein.
Intentionally designed and screened for the
development of rapid saliva antigen tests, these antibodies
recognize a linear epitope of the SARS-CoV-S1 trimeric protein. The
antibody pair is the first-of-its-kind, having sensitivity down to
picograms per milliliter as measured by ELISA. Further, the
antibody pair is highly specific to the SARS-CoV-2 trimeric spike
protein and does not cross react with other coronaviruses, such as
SARS-CoV, HCoV-229F, HCoV-HKUI, HCoV-NL63 and HCoV-OC43.
“Meridian has already enabled the manufacture of
millions of COVID-19 assays dating back to the early days of the
pandemic. This new antibody pair reflects Meridian’s on-going
commitment to be the leading partner to the diagnostics industry
through continuous innovation, enhancing the tools R&D teams
have to fight this global pandemic,” said Todd Howren, Ph.D., Vice
President Global Sales for Meridian Bioscience, Life Science
Division. “A rapid COVID-19 antigen assay from saliva, which does
not sacrifice sensitivity, is now possible due to this novel
antibody pair.”
“Accelerated scale-up efforts of this antibody
pair are now in progress and Meridian is excited to partner with
our IVD customers to bring rapid antigen COVID-19 assays to market”
said Lourdes Weltzien, Ph.D., Executive Vice President for Meridian
Bioscience, Life Science Division.
Meridian is committed to
supplying innovative solutions to the diagnostic industry
during times of a pandemic health crisis. For more information on
partnering with Meridian Bioscience please visit
meridianlifescience.com or contact:
lourdes.weltzien@meridianbioscience.com.
About Meridian Bioscience,
Inc.
Meridian is a fully integrated life science
company that develops, manufactures, markets and distributes a
broad range of innovative diagnostic products. We are dedicated to
developing and delivering better solutions that give answers with
speed, accuracy and simplicity that are redefining the
possibilities of life from discovery to diagnosis. Through
discovery and development, we provide critical life science raw
materials used in immunological and molecular tests for human,
animal, plant, and environmental applications. Through diagnosis,
we provide diagnostic solutions in areas including gastrointestinal
and upper respiratory infections and blood lead level testing. We
build relationships and provide solutions to hospitals, reference
laboratories, research centers, veterinary testing centers,
physician offices, diagnostics manufacturers, and biotech companies
in more than 70 countries around the world.
Meridian’s shares are traded on the NASDAQ
Global Select Market, symbol VIVO. Meridian’s website address is
www.meridianbioscience.com.
Contact:Charlie WoodVice
President – Investor RelationsMeridian Bioscience, Inc.Phone: +1
513.271.3700Email: mbi@meridianbioscience.com
Meridian Bioscience (NASDAQ:VIVO)
Historical Stock Chart
From Jun 2024 to Jul 2024
Meridian Bioscience (NASDAQ:VIVO)
Historical Stock Chart
From Jul 2023 to Jul 2024